Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial

A phase III randomized controlled trial published in The Lancet evaluated the efficacy of the PD-1 inhibitor Nivolumab in patients with previously treated advanced gastric cancer, finding found Nivolumab improved overall survival compared with the placebo.